Download or read book Serum Free Light Chain Analysis written by A. R. Bradwell and published by . This book was released on 2006 with total page 310 pages. Available in PDF, EPUB and Kindle. Book excerpt:

Download or read book Serum Free Light Chain Analysis written by A. R. Bradwell and published by . This book was released on 2008 with total page 312 pages. Available in PDF, EPUB and Kindle. Book excerpt:

Download or read book Mosby s Manual of Diagnostic and Laboratory Tests written by Kathleen Deska Pagana and published by Mosby. This book was released on 2017-10-27 with total page 1137 pages. Available in PDF, EPUB and Kindle. Book excerpt: "Succeed iin clinicals and practice with this user-friendly diagnostic and lab test manual. Writing care plans, understanding and performing tests, and interpreting test results is made easier with Mosby's Manual of Diagnostic and Laboratory Tests, 6th Edition. This essential resource provides clear, concise coverage of over 700 of the most commonly performed diagnostic and laboratory tests. Valuable in academic and clinical settings alike, it is beloved for its full-color design, user-friendly organization, andillustrations that help clarify key concepts" -- Back cover.

Download or read book Contemporary Practice in Clinical Chemistry written by William Clarke and published by Academic Press. This book was released on 2020-06-11 with total page 1070 pages. Available in PDF, EPUB and Kindle. Book excerpt: Contemporary Practice in Clinical Chemistry, Fourth Edition, provides a clear and concise overview of important topics in the field. This new edition is useful for students, residents and fellows in clinical chemistry and pathology, presenting an introduction and overview of the field to assist readers as they in review and prepare for board certification examinations. For new medical technologists, the book provides context for understanding the clinical utility of tests that they perform or use in other areas in the clinical laboratory. For experienced laboratorians, this revision continues to provide an opportunity for exposure to more recent trends and developments in clinical chemistry. Includes enhanced illustration and new and revised color figures Provides improved self-assessment questions and end-of-chapter assessment questions

Download or read book The Saint Chopra Guide to Inpatient Medicine written by Sanjay Saint and published by Oxford University Press, USA. This book was released on 2018 with total page 609 pages. Available in PDF, EPUB and Kindle. Book excerpt: Preceded by: Clinical clerkship in inpatient medicine / Sanjay Saint. 3rd ed. c2010.

Download or read book Hematologic Malignancies written by Manorama Bhargava and published by Springer Nature. This book was released on 2021-02-13 with total page 246 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book is a compendium of case studies in hematologic malignancies such as acute leukemias, myelodysplastic and myeloproliferative neoplasms, chronic leukemias and multiple myeloma covering cytogenetics (karyotyping Fluorescence in sitn hybridization (FISH)) and molecular studies in detail. The first few chapters describe the methodology employed for karyotyping, FISH and Real Time PCR technology conducive to establishment of these labs if required. Each case study is described in detail by including the clinical history of the patient, findings of peripheral blood, bone marrow aspirate and bone biopsy morphological details. This is then followed by flowcytometric immunophenotyping, cytogenetic and molecular observations leading collectively to a final diagnosis, A discussion follows based on the relevance of this data in informing the prognosis, treatment response and survival in these patients. Additionally, this data serves as a key determinant for clinical decision making involving evidence based rational management of patients including targeted therapy. For better understanding, each case study is accompanied by black and white or colour images as appropriate. This book is a source of learning and a valuable read for clinical hematologists, hematopathologists, medical oncologists, residents, interns, DM Hematology students and DNB Hematology students as well.

Download or read book Cancer and the Kidney written by Eric P. Cohen and published by Oxford University Press, USA. This book was released on 2010-11-11 with total page 382 pages. Available in PDF, EPUB and Kindle. Book excerpt: Cancer and the Kidney covers the challenging overlap area of nephrology and oncology, both in terms of kidney problems in cancer patients, and cancer that affects kidney patients, including assessment of kidney function, to paraneoplastic disorders, acquired cysts and native kidney cancers, and all points inbetween.

Download or read book Serum Free Light Chain Analysis for the Diagnosis Management and Prognosis of Plasma Cell Dyscrasias written by Madhumathi Rao and published by . This book was released on 2012 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt: Plasma cell dyscrasias (PCDs) are a group of clonal disorders characterized by the uninhibited expansion of a monoclonal population of malignant plasma cells. Plasma cells arise from B cells in the bone marrow and produce immunoglobulins that constitute the body's normal humoral immune response. The immunoglobulin molecule is composed of a heavy chain and a light chain. Plasma cells normally produce light chains in excess that do not bind to heavy chains to form a complete immunoglobulin molecule and instead enter the bloodstream as free light chains (FLCs). In PCDs, each abnormally expanded clone of malignant plasma cells produce an excess of either intact immunoglobulin or FLCs of a single type called a monoclonal protein (M-protein) or paraprotein. The serum FLC (SFLC assay (the Freelite" Assay), The Binding Site Ltd., Birmingham, United Kingdom) was introduced in 2001 to measure the FLC component in particular. The SFLC assay works by recognizing an epitope that is detectable only on light chains that are not bound to the heavy chain of the immunoglobulin molecule (i.e., FLCs) in the serum. This is the sole SFLC assay approved by the U.S. Food and Drug Administration. It detects low concentrations of FLCs and can measure the ratio of kappa chains to lambda chains. It has been suggested that the SFLC assay could play an adjunctive role in screening, diagnosis, monitoring, and prognosis of PCDs in high-risk populations. The International Myeloma Working Group (IMWG) currently considers the SFLC assay to be an adjunct to traditional tests. The assay could allow for quantitative monitoring of response and remission after treatment and provide prognostic information, potentially reducing the need for frequent bone marrow biopsy for purposes of quantifying plasma cells, which is required as part of stringent monitoring for monoclonal gammopathy of undetermined significance (MGUS) progression to multiple myeloma (MM) or defining disease remission, and potentially could be used in conjunction with serum protein electrophoresis (SPEP) and serum immunofixation electrophoresis (SIFE) to replace urine tests that require 24-hour collection (urine protein electrophoresis [UPEP] and urine immunofixation electrophoresis [UIFE]), which could simplify diagnosis and disease monitoring. The SFLC assay may also be the only means of detecting a disease marker in some disease settings: nonsecretory MM, where SFLCs are often the only marker of the disease; AL amyloidosis (systemic amyloidosis in which amyloid [A] proteins derived from immunoglobulin light chains [L] are deposited in tissue), where low monoclonal protein (M-protein) concentrations may not be detected by means of conventional techniques; and light chain MM, where the M-protein consists only of FLCs. These diagnostic applications have yet to be validated and standardized. Thus, although the SFLC assay has been in use for a decade, it remains unclear how best to incorporate it into clinical practice.

Download or read book Protein Electrophoresis in Clinical Diagnosis written by David Keren and published by CRC Press. This book was released on 2003-09-26 with total page 415 pages. Available in PDF, EPUB and Kindle. Book excerpt: Since the publication of High-Resolution Electrophorsesis and Immunofixation 2e, there have been ever-increasing advances in the analyses of proteins, by electrophoresis in particular. Protein Electrophoresis in Clinical Diagnosis shows the changes in both techniques and interpretation, presenting a comprehensive review of serum protein techniques,

Download or read book Multiple Myeloma written by Morie A. Gertz and published by Springer Science & Business Media. This book was released on 2013-10-01 with total page 311 pages. Available in PDF, EPUB and Kindle. Book excerpt: This is a comprehensive, state-of-the-art guide to the diagnosis, treatment, and biology of multiple myeloma and related plasma disorders. Edited and written by a multidisciplinary group of recognized authorities from the Mayo Clinic, it presents clear guidelines on diagnosis and therapy and covers all aspects of multiple myeloma, from molecular classification and diagnosis, to risk stratification and therapy. Closely related plasma cell disorders such as solitary plasmacytoma, Waldenstrom macroglobulinemia, and light chain amyloidosis are discussed in detail as well. The book addresses often overlooked topics, including the role of radiation therapy, vertebral augmentation, and supportive care. Our understanding of this group of disorders is developing at an unprecedented rate, and Multiple Myeloma meets the need among oncologists and hematologists for a clear, timely, and authoritative resource on their biology, diagnosis, and treatment.

Download or read book Serum Free Light Chain Analysis for the Diagnosis Management and Prognosis of Plasma Cell Dyscrasias Future Research Needs written by U. S. Department of Health and Human Services and published by Createspace Independent Pub. This book was released on 2013-05-23 with total page 54 pages. Available in PDF, EPUB and Kindle. Book excerpt: Plasma cell dyscrasias (PCDs) are a group of clonal disorders characterized by the uninhibited expansion of a monoclonal population of malignant plasma cells. Plasma cells arise from B cells in the bone marrow and produce immunoglobulins that constitute the body's normal humoral immune response. The immunoglobulin molecule is composed of a heavy chain and a light chain. Plasma cells normally produce light chains in excess that do not bind to heavy chains to form a complete immunoglobulin molecule and instead enter the bloodstream as free light chains (FLCs). In PCDs, each abnormally expanded clone of malignant plasma cells produce an excess of either intact immunoglobulin or FLCs of a single type called a monoclonal protein (Mprotein) or paraprotein. The serum FLC (SFLC assay (the Freelite(tm) Assay, The Binding Site Ltd., Birmingham, United Kingdom) was introduced in 2001 to measure the FLC component in particular. The SFLC assay works by recognizing an epitope that is detectable only on light chains that are not bound to the heavy chain of the immunoglobulin molecule (i.e., FLCs) in the serum. It has been suggested that the SFLC assay could play an adjunctive role in screening, diagnosis, monitoring, and prognosis of PCDs in high-risk populations. The assay could allow for quantitative monitoring of response and remission after treatment and provide prognostic information, potentially reducing the need for frequent bone marrow biopsy for purposes of quantifying plasma cells, which is required as part of stringent monitoring for monoclonal gammopathy of undetermined significance (MGUS) progression to multiple myeloma (MM) or defining disease remission, and potentially could be used in conjunction with serum protein electrophoresis (SPEP) and serum immunofixation electrophoresis (SIFE) to replace urine tests that require 24-hour collection (urine protein electrophoresis [UPEP] and urine immunofixation electrophoresis [UIFE]), which could simplify diagnosis and disease monitoring. The SFLC assay may also be the only means of detecting a disease marker in some disease settings: nonsecretory MM, where SFLCs are often the only marker of the disease; AL amyloidosis (systemic amyloidosis in which amyloid [A] proteins derived from immunoglobulin light chains [L] are deposited in tissue), where low monoclonal protein (M-protein) concentrations may not be detected by means of conventional techniques; and light chain MM, where the M-protein consists only of FLCs. The following Key Questions are reviewed. KQ 1: Does adding the SFLC assay and the kappa/lambda ratio to traditional testing (SPEP, UPEP, SIFE, or UIFE), compared with traditional testing alone, improve the diagnostic accuracy for PCDs (MGUS, MM, nonsecretory MM, or AL amyloidosis) in undiagnosed patients suspected of having a PCD? KQ 2: As compared with traditional tests, how well does the SFLC assay independently predict progression to MM in patients with MGUS? KQ 3: In patients with an existing diagnosis of PCD (MM, nonsecretory MM, or AL amyloidosis), does the use of the SFLC assay result in different treatment decisions as compared with traditional tests? Does the use of the SFLC assay affect the management of patients by allowing for earlier institution of specific therapies? Does the use of the SFLC assay influence the duration of treatment? Does the use of the SFLC assay influence the type of treatment (e.g., radiation therapy)? KQ4: In patients with an existing diagnosis of PCD (MM, nonsecretory MM, or AL amyloidosis), is the SFLC assay better than traditional tests in indicating how the patient responds to treatment and of outcomes (overall survival, disease-free survival, remission, light chain escape, and quality of life)? KQ 5: In patients with an existing diagnosis of PCD (MM, nonsecretory MM, or AL amyloidosis), does the use of the SFLC assay reduce the need for other interventions (e.g., bone marrow biopsy)?

Download or read book The EBMT Handbook written by Nicolaus Kröger and published by . This book was released on 2020-10-08 with total page 688 pages. Available in PDF, EPUB and Kindle. Book excerpt: This Open Access edition of the European Society for Blood and Marrow Transplantation (EBMT) handbook addresses the latest developments and innovations in hematopoietic stem cell transplantation and cellular therapy. Consisting of 93 chapters, it has been written by 175 leading experts in the field. Discussing all types of stem cell and bone marrow transplantation, including haplo-identical stem cell and cord blood transplantation, it also covers the indications for transplantation, the management of early and late complications as well as the new and rapidly evolving field of cellular therapies. This book provides an unparalleled description of current practices to enhance readers' knowledge and practice skills. This work was published by Saint Philip Street Press pursuant to a Creative Commons license permitting commercial use. All rights not granted by the work's license are retained by the author or authors.

Download or read book Serum Free Light Chain Analysis Plus Hevylite written by A. R. Bradwell and published by . This book was released on 2010 with total page 350 pages. Available in PDF, EPUB and Kindle. Book excerpt:

Download or read book Oxford Textbook of Clinical Nephrology written by Neil N. Turner and published by Oxford University Press. This book was released on 2015-10-29 with total page 3045 pages. Available in PDF, EPUB and Kindle. Book excerpt: This fourth edition of the Oxford Textbook of Clinical Nephrology builds on the success and international reputation of the publication as an important resource for the practising clinician in the field. It provides practical, scholarly, and evidence-based coverage of the full spectrum of clinical nephrology, written by a global faculty of experts. The most relevant and important reference to clinical nephrology, this is an authoritative and comprehensive textbook combining the clinical aspects of renal disease essential to daily clinical practice with extensive information about the underlying basic science and current evidence available. Each section of the textbook has been critically and comprehensively edited under the auspices of a leading expert in the field. This new edition has been significantly expanded and reapportioned to reflect developments and new approaches to topics, and includes treatment algorithms to aid and enhance patient care where possible. The fourth edition offers increased focus on the medical aspects of transplantation, HIV-associated renal disease, and infection and renal disease, alongside entirely new sections on genetic topics and clinical and physiological aspects of fluid/electrolyte and tubular disorders. The emphasis throughout is on marrying advances in scientific research with clinical management. Richly illustrated throughout in full colour, this is a truly modern and attractive edition which reinforces the Oxford Textbook of Clinical Nephrology's position as an indispensable reference work of consistent quality and reliability. Enriched and refined by careful revision, this new edition continues the tradition of excellence. This print edition of The Oxford Textbook of Clinical Nephrology comes with a year's access to the online version on Oxford Medicine Online. By activating your unique access code, you can read and annotate the full text online, follow links from the references to primary research materials, and view, enlarge and download all the figures and tables. Oxford Medicine Online is mobile optimized for access when and where you need it.

Download or read book Cardiac Markers written by Alan H. B. Wu and published by Springer Science & Business Media. This book was released on 2003-06-12 with total page 460 pages. Available in PDF, EPUB and Kindle. Book excerpt: In this greatly enlarged and thoroughly updated edition of his much praised Cardiac Markers, Alan Wu and his contributors focus on the use of markers in the practice of cardiology and-for the first time-on the use of natriuretic peptides for congestive heart failure. Here, leading international authorities in clinical chemistry and laboratory medicine, cardiology, emergency medicine, and the in vitro diagnostics industry describe the state-of-the-art uses of cardiac markers when treating coronary artery disease, and discuss in detail how they may be optimally used in a clinical setting. Comprehensive and cutting-edge, Cardiac Markers, Second Edition offers physicians a complete guide to the use of cardiac markers in clinical practice and clinical laboratorians a close-up view of the new markers now becoming standard.

Download or read book Hypercalcemia of Malignancy written by Friedhelm Raue and published by Springer Science & Business Media. This book was released on 2012-12-06 with total page 238 pages. Available in PDF, EPUB and Kindle. Book excerpt: Hypercalcemia is the most common life-threatening metabolic disorder associated with cancer. The pathophysiological, epidemiological and clinical aspects of hypercalcemia of malignancy are presented in this issue, with a focus on the recently discovered humoral factor responsible for the development of hypercalcemia. With a better understanding of the pathophysiology of this condition and the development of new potent drugs, capable of inhibiting bone resorption, especially bisphosphonates, the clinician will be more successful in correcting hypercalcemia in the great majority of patients.

Download or read book Waldenstr m s Macroglobulinemia written by Véronique Leblond and published by Springer. This book was released on 2016-10-06 with total page 361 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book sheds new light on clinical, biological and therapeutic data on the rare disease Waldenström’s Macroglobulinemia (WM) with the participation of widely-recognized experts, involved in this field. It represents the efforts of physicians, scientists and patients, all around the world, to better understand and cure this rare disease. Considerable advances in the diagnosis, treatment indications, response criteria, prognostic factors and treatment options have been made since Dr Jan Waldenström first reported this “new syndrome“ 70 years ago. Particularly instrumental in advancing of our understanding of WM have been the eight international workshops devoted to this disease. New, exciting molecular data have recently been reported, allowing us to revisit the oncogenic events leading to WM B-cell proliferation and to use newly available compounds targeting oncogenic pathways.